Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
34.13
+0.62 (1.85%)
At close: Jun 2, 2025, 4:00 PM
34.11
-0.02 (-0.06%)
After-hours: Jun 2, 2025, 4:55 PM EDT
Ionis Pharmaceuticals Revenue
Ionis Pharmaceuticals had revenue of $131.61M in the quarter ending March 31, 2025, with 10.14% growth. This brings the company's revenue in the last twelve months to $717.25M, down -7.64% year-over-year. In the year 2024, Ionis Pharmaceuticals had annual revenue of $705.14M, down -10.48%.
Revenue (ttm)
$717.25M
Revenue Growth
-7.64%
P/S Ratio
7.14
Revenue / Employee
$670,957
Employees
1,069
Market Cap
5.43B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 705.14M | -82.51M | -10.48% |
Dec 31, 2023 | 787.65M | 200.28M | 34.10% |
Dec 31, 2022 | 587.37M | -223.09M | -27.53% |
Dec 31, 2021 | 810.46M | 81.19M | 11.13% |
Dec 31, 2020 | 729.26M | -393.34M | -35.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IONS News
- 14 days ago - Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides - Business Wire
- 27 days ago - Ionis to host 2025 virtual Annual Meeting of Stockholders - Business Wire
- 4 weeks ago - Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge - Benzinga
- 4 weeks ago - Ionis reports first quarter 2025 financial results - Business Wire
- 4 weeks ago - New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies - Business Wire
- 5 weeks ago - Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade) - Seeking Alpha
- 2 months ago - Ionis to host expert panel discussion on sHTG - Business Wire